Pentax Medical Acquires C2 Therapeutics

Medical imaging equipment manufacturer Pentax Medical has acquired ablation developer C2 Therapeutics for an undisclosed amount.

C2 Therapeutics produces the C2 CryoBalloon Ablation System for the endoscopic ablation of unwanted tissue such as Barrett's esophagus.

"The C2 CryoBalloon Ablation System has the potential to improve the lives of millions of people around the world with pre-cancerous lesions of the esophagus,” said David Woods, global chief marketing officer of Pentax Medical.

Barrett's esophagus and squamous dysplasia are both conditions in which the epithelial cells in the lining of the esophagus abnormally change to form pre-cursor lesions. If left untreated, these lesions can progress to esophageal cancer in some patients. The C2 CryoBalloon Ablation System provides the interventional endoscopist with a means to deliver a targeted dose of cryogen to ablate these tissues immediately. Esophageal cancer is the sixth leading cause of cancer deaths in the world with a five-year survival rate of 18 percent and is the fastest growing form of cancer in the United States today.

Pentax Medical provides endoscopic imaging devices and solutions to the global medical community. C2 Therapeutics is focused on eliminating pre-cancerous conditions and adjunctive treatment in cancer in gastroenterology and pulmonary.